Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Long-Term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis With Up to 5 Years of Follow-UpOncologist 2021 Jan 23;[EPub Ahead of Print], RS Finn, HS Rugo, KA Gelmon, M Cristofanilli, M Colleoni, S Loi, P Schnell, DR Lu, KP Theall, A Mori, E Gauthier, E Bananis, NC Turner, V Diéras
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.